

Hansa Medical

- PRESS RELEASE -
9 November 2016

Hansa Medical's Nomination Committee for the AGM 2017 appointed

In accordance with the decision of the Annual General Meeting on May 11, 2016, a Nomination Committee for the Hansa Medical AGM 2017 has been formed. Based on the list of shareholders as of 31 August 2016, the three largest shareholders have been contacted and invited to each appoint a representative to the Nomination Committee. The Nomination Committee consists of Erika Kjellberg Eriksson representing Nexttobe AB, Max Mitteregger representing Gladiator and Fredrik Bogren representing Farstorps Gård AB. The Nomination Committee also includes the chairman of the board, Ulf Wiinberg, as convener. Furthermore, the company publishes financial calendar for 2017.

The function of the Nomination Committee is to prepare and submit proposals for the AGM regarding the number of board members to be elected by the general meeting, election of chairman and other board members, board fees and any remuneration for committee work, election of chairman of the Annual General Meeting, election of auditors (if applicable) and the auditors and proposals for rules for the Nominating Committee for the AGM in 2018.

The Annual General Meeting of Hansa Medical AB (publ) will be held May 25, 2017 in the Auditorium (Hörsalen) by the company's premises at Scheelevägen 22 in Lund.

Shareholders wishing to submit comments or submit proposals to the Nomination Committee may do so no later than 24 March 2017 via email to info@hansamedical.com or by letter to Hansa Medical, Nomination Committee, Box 785, 220 07 Lund, Sweden.

The Nomination Committee's proposals will be presented in the notice convening the AGM and on the company's website.

Financial calendar

Extraordinary General Meeting	21 November 2016
Year-end report 2016	15 February 2017
Annual Report 2016	26 April, 2017
Annual General Meeting 2017	25 May 2017

For further information, please contact:

Göran Arvidson, CEO, Hansa Medical AB (publ)
Mobile: +4670633 3042
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com

This information is such information that Hansa Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:00 am CEST on 9 November 2016.

About Hansa Medical AB (publ)

Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation, rare autoimmune diseases and oncology. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical's share (ticker: HMED) is listed on Nasdaq Stockholm.